Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

• Status: Unknown status
• Trial end date: 1969-12-31

Summary

The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.

• Phase: Phase 2

Details

• Lead Sponsor: Johann Wolfgang Goethe University Hospital
• Treatments: Imatinib Mesylate; Mitoxantrone; Topotecan